Evaluation for synergistic suppression of breast cancer proliferation by Chloroquine in combination with the rapamycin derivative, Rad001

Fragestellung: Breast cancer remains the most prevalent cancer among women in the Western world. Interactions between the p53 and the IGF-1/PI3K/Akt/mTOR pathway are present in many cancer cells. Therapeutical modification of each of these two pathways has been proven to exert anti-tumoral effects. The macrolide derivative of rapamycin Rad001 (everolimus) is an inhibitor of the serine-threonine kinase mTOR, and has been developed as an anti-proliferative drug with applications as an immunosuppressant and anticancer agent.